The screening of volatile markers for hepatocellular carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 9, 2010, Pages 2247-2253

  Qin, Tao ^a   Liu, Hu ^a   Song, Qi ^a   Song, Geng ^a   Wang, Hong Zhi ^b   Pan, Yue Yin ^a   Xiong, Fu Xing ^a   Gu, Kang Sheng ^a   Sun, Guo Ping ^a   Chen, Zhen Dong ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b HEFEI INSTITUTES OF PHYSICAL SCIENCE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOIN; ALPHA FETOPROTEIN; DECANE; STYRENE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISCRIMINANT ANALYSIS; FEMALE; GAS CHROMATOGRAPHY; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MASS SPECTROMETRY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDITY;

ACETOIN; ALKANES; BREATH TESTS; CARCINOMA, HEPATOCELLULAR; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; STYRENE; TUMOR MARKERS, BIOLOGICAL; VOLATILE ORGANIC COMPOUNDS;

EID: 77956498657     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0302     Document Type: Article

References (25)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
2. Tang ZY. Hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15 Suppl:G1-7.
3. Jia HL, Xing XJ, Ye QH, Qin LX. Application of α-fetoprotein in the diagnosis of hepatocellular carcinoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2008;30:440-3.
4. Pauling L, Robinson AB, Teranishi R, Carry P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci U S A 1971;68:2374-6.
5. Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr 2007;21:553-66. (Pubitemid 46937852)
6. Amann A, Schmid A, Scholl-Burgi S, Tesler S, Hinterhuber H. Breath analysis for medical diagnosis and therapeutic monitoring. Spectroscopy Europe 2005;17:18-20. (Pubitemid 40952386)
7. Bajtarevic A, Ager C, Pienz M, et al. Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 2009;9:348.
8. Schubert JK, Miekisch W, Birken T, Geiger K, Nöldge-Schomburg GF. Impact of inspired substance concentrations onto results of breath analysis in mechanically ventilated patients. Biomarkers 2005;10:138-52. (Pubitemid 40916672)
9. Ligor M, Ligor T, Bajtarevic A, et al. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry. Clin Chem Lab Med 2009;47:550-60.
10. Buszewski B, Ulanowska A, Ligor T, Denderz N, Amann A. Analysis of exhaled breath from smokers, passive smokers and non-smokers by solid-phase microextraction gas chromatography/mass spectrometry. Biomed Chromatogr 2009;23:551-6.
11. Miekisch W, Kischkel S, Sawacki A, Liebau T, Mieth M, Schubert JK. Impact of sampling procedures on the results of breath analysis. J Breath Res 2008;2:026007.
12. Gordon SM, Szidon JP, Krotoszynski BK, Gibbons RD, O'Neill HJ. Volatile organic compounds in exhaled air from patients with lung cancer. Clin Chem 1985;31:1278-82.
13. O'Neill HJ, Gordon SM, O'Neill MH, Gibbons RD, Szidon JP. A computerized classification technique for screening for the presence of breath biomarkers in lung cancer. Clin Chem 1988;34:1613-8.
14. Phillips M, Gleeson K, Hughes JM, et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999;353:1930-3. (Pubitemid 29255706)
15. Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 2005;171:1286-91. (Pubitemid 40740737)
16. Poli D, Carbognani P, Corradi M, et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 2005;6:71. (Pubitemid 41410164)
17. Song G, Qin T, Liu H, et al. Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer 2010;67:227-31.
18. Phillips M, Cataneo RN, Ditkoff BA, et al. Volatile markers of breast cancer in the breath. Breast J 2003;9:184-91. (Pubitemid 36627163)
19. Phillips M, Cataneo RN, Ditkoff BA, et al. Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res Treat 2006;99:19-21. (Pubitemid 44168599)
20. Schmutzhard J, Rieder J, Deibl M, et al. Pilot study: volatile organic compounds as a diagnostic marker for head and neck tumors. Head Neck 2008;30:743-9. (Pubitemid 351913850)
21. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
22. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepato 2008;l23:512-20.
23. Soresi M, Magliarisi C, Campagna P, et al. Usefulness of α-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003;23:1747-53. (Pubitemid 36750842)
24. Chen X, Xu F, Wang Y, et al. A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. Cancer 2007;110:835-44. (Pubitemid 47257662)
25. Phillips M, Altorki N, Austin JH, et al. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark 2007;3:95-109. (Pubitemid 47103811)